
Quarterly report 2024-Q1
                    added 05-14-2024
Motus GI Holdings Financial Statements 2011-2025 | MOTS
Annual Financial Statements Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | 
                            
                            990 K | 261 K | 863 K | 46.2 M | 50.8 M | 62.8 M | - | - | - | - | - | - | - | 
                            
                                Shares | 
                            
                            1.55 M | 310 K | 2.42 M | 32.1 M | 25.1 M | 15.1 M | - | - | - | - | - | - | - | 
Historical Prices | 
                            
                            0.64 | 0.84 | 0.357 | 1.44 | 2.04 | 4.1 | - | - | - | - | - | - | - | 
Net Income | 
                            
                            -12.9 M | -18.6 M | -19 M | -19.3 M | -23.1 M | -22.3 M | -13.2 M | -8.02 M | -5.99 M | - | - | - | - | 
Revenue | 
                            
                            319 K | 592 K | 391 K | 98 K | 107 K | 36 K | 7 K | - | - | - | - | - | - | 
Cost of Revenue | 
                            
                            81 K | 198 K | 181 K | 95 K | 136 K | 54 K | - | - | - | - | - | - | - | 
Gross Profit | 
                            
                            - | - | - | -398 K | -29 K | -18 K | 4 K | - | - | - | - | - | - | 
Operating Income | 
                            
                            -11.9 M | -17.9 M | -17.9 M | -19 M | -23.4 M | -18.9 M | -13 M | - | - | - | - | - | - | 
Interest Expense | 
                            
                            211 | 128 | 453 K | - | - | - | - | - | - | - | - | - | - | 
EBITDA | 
                            
                            -11.5 M | -17.3 M | -17.5 M | -18.7 M | -23.2 M | -18.7 M | -12.9 M | -7.87 M | -5.91 M | - | - | - | - | 
Operating Expenses | 
                            
                            - | - | - | 18.6 M | 23.4 M | 18.9 M | 13 M | - | - | - | - | - | - | 
General and Administrative Expenses | 
                            
                            6.58 M | 7.61 M | 9.27 M | 9.56 M | 9.5 M | 8.55 M | 6.29 M | 1.86 M | 1.74 M | - | - | - | - | 
All numbers in USD currency
Quarterly Income Statement Motus GI Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
                            
                                Shares | 
                            
                            5.21 M | 1.55 M | 530 K | 5.31 M | 4.78 M | 310 K | 3.03 M | 2.77 M | 55.1 M | 2.42 M | 48.2 M | 47.7 M | 42.2 M | 32.3 M | 30.4 M | 28.8 M | 28.8 M | 28.8 M | 28.7 M | 21.5 M | 21.4 M | 21.4 M | 15.7 M | 15.6 M | 12.9 M | 10.5 M | 10.5 M | 10.5 M | 9.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Net Income | 
                            
                            -2.11 M | - | -2.68 M | -3 M | -4.39 M | - | -4.96 M | -5.14 M | -4.81 M | - | -4.82 M | -4.74 M | -4.65 M | - | -3.94 M | -4.41 M | -6.51 M | - | -5.2 M | -5.68 M | -6.27 M | - | -5.17 M | -4.2 M | -7.32 M | - | -3.16 M | -3.48 M | -2.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Revenue | 
                            
                            64 K | - | 86 K | 113 K | 56 K | - | 278 K | 185 K | 20 K | - | 141 K | 100 K | 51 K | - | 33 K | 1 K | 28 K | - | 3 K | 4 K | 1 K | - | 38 K | 26 K | 12 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Cost of Revenue | 
                            
                            12 K | - | 22 K | 31 K | 9 K | - | 83 K | 68 K | 15 K | - | 65 K | 42 K | 28 K | - | 32 K | 10 K | 30 K | - | 62 K | 2 K | 1 K | - | 56 K | 41 K | 15 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Gross Profit | 
                            
                            - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | -9 K | -2 K | - | -59 K | 2 K | - | - | -18 K | -15 K | -3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Operating Income | 
                            
                            -2.03 M | - | -2.39 M | -2.68 M | -4.36 M | - | -4.7 M | -4.59 M | -4.53 M | - | -4.34 M | -4.59 M | -4.44 M | - | -3.82 M | -4.22 M | -6.71 M | - | -5.42 M | -5.65 M | -6.36 M | - | -5.13 M | -4.13 M | -4.08 M | - | -3.99 M | -2.51 M | -2.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Interest Expense | 
                            
                            85 K | - | 281 K | 285 K | 308 K | - | 338 K | 356 K | 327 K | - | 193 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
EBITDA | 
                            
                            -1.93 M | - | -2.28 M | -2.57 M | -4.24 M | - | -4.58 M | -4.46 M | -4.4 M | - | -4.22 M | -4.49 M | -4.34 M | - | -3.67 M | -4.1 M | -6.64 M | - | -5.36 M | -5.6 M | -6.31 M | - | -5.09 M | -4.09 M | -4.05 M | - | -3.95 M | -2.48 M | -2.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Operating Expenses | 
                            
                            - | - | - | - | - | - | - | - | - | - | -5 K | - | 4.49 M | - | 3.82 M | 4.21 M | 6.74 M | - | 5.36 M | 5.65 M | 6.36 M | - | 5.13 M | 4.11 M | 4.08 M | - | 3.99 M | 2.51 M | 2.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
General and Administrative Expenses | 
                            
                            1.47 M | - | 1.55 M | 1.64 M | 1.94 M | - | 1.98 M | 2.08 M | 2.11 M | - | 2.32 M | 2.34 M | 9 K | - | 2.16 M | 2.36 M | 19 K | - | 2.03 M | 2.36 M | 2.8 M | - | 2.14 M | 1.74 M | 2.13 M | - | 2.41 M | 840 K | 1.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
All numbers in USD currency
Main types of financial statements Motus GI Holdings MOTSFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities. 
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
 - GAAP — Generally Accepted Accounting Principles used in the United States.
 - RAS — Russian Accounting Standards, used domestically in Russia.
 
Financial reporting Motus GI Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
| 
              
              Centogene N.V.
               CNTG 
              
             | 
            
              $ 0.33 | -6.23 % | $ 30.6 M | ||
| 
              
              Fluidigm Corporation
               FLDM 
              
             | 
            
              $ 3.75 | 1.08 % | $ 308 M | ||
| 
              
              Global Cord Blood Corporation
               CO 
              
             | 
            
              $ 2.99 | - | $ 399 M | ||
| 
              
              Oxford Immunotec Global PLC
               OXFD 
              
             | 
            
              $ 21.99 | - | $ 562 M | ||
| 
              
              Genetron Holdings Limited
               GTH 
              
             | 
            
              $ 4.03 | 0.12 % | $ 80.1 M | ||
| 
              
              Chembio Diagnostics
               CEMI 
              
             | 
            
              $ 0.46 | 0.22 % | $ 16.8 M | ||
| 
              
              Pacific Biosciences of California
               PACB 
              
             | 
            
              $ 2.23 | -4.91 % | $ 566 M | ||
| 
              
              Koninklijke Philips N.V.
               PHG 
              
             | 
            
              $ 27.4 | 0.31 % | $ 20 B | ||
| 
              
              Meridian Bioscience
               VIVO 
              
             | 
            
              $ 33.97 | - | $ 1.49 B | ||
| 
              
              HTG Molecular Diagnostics
               HTGM 
              
             | 
            
              $ 0.48 | -20.0 % | $ 1.06 M | ||
| 
              
              Quidel Corporation
               QDEL 
              
             | 
            
              $ 27.64 | 2.39 % | $ 1.16 B | ||
| 
              
              Quotient Limited
               QTNT 
              
             | 
            
              $ 0.32 | -11.32 % | $ 1.1 M | ||
| 
              
              Bioventus 
               BVS 
              
             | 
            
              $ 6.58 | 0.38 % | $ 412 M | ||
| 
              
              PRA Health Sciences, Inc.
               PRAH 
              
             | 
            
              $ 165.21 | - | $ 10.7 B | ||
| 
              
              Thermo Fisher Scientific 
               TMO 
              
             | 
            
              $ 564.29 | -0.48 % | $ 216 B | ||
| 
              
              Twist Bioscience Corporation
               TWST 
              
             | 
            
              $ 31.45 | -4.38 % | $ 1.82 B | ||
| 
              
              Heska Corporation
               HSKA 
              
             | 
            
              $ 119.99 | - | $ 1.31 B | ||
| 
              
              Biocept
               BIOC 
              
             | 
            
              $ 0.43 | -13.05 % | $ 7.29 M | ||
| 
              
              Syneos Health
               SYNH 
              
             | 
            
              $ 42.98 | - | $ 4.46 B | ||
| 
              
              Invitae Corporation
               NVTA 
              
             | 
            
              $ 0.09 | - | $ 21.2 M | ||
| 
              
              DermTech
               DMTK 
              
             | 
            
              $ 0.09 | -11.32 % | $ 2.94 M | ||
| 
              
              Akumin
               AKU 
              
             | 
            
              $ 0.29 | -17.87 % | $ 25.9 M | ||
| 
              
              Castle Biosciences
               CSTL 
              
             | 
            
              $ 25.99 | 1.9 % | $ 722 M | ||
| 
              
              DarioHealth Corp.
               DRIO 
              
             | 
            
              $ 13.51 | -3.43 % | $ 383 M | ||
| 
              
              Exagen 
               XGN 
              
             | 
            
              $ 11.86 | 1.63 % | $ 210 M | ||
| 
              
              PerkinElmer
               PKI 
              
             | 
            
              $ 115.24 | -0.91 % | $ 14.7 B | ||
| 
              
              OpGen
               OPGN 
              
             | 
            
              $ 1.96 | -16.95 % | $ 1.54 M | ||
| 
              
              DexCom
               DXCM 
              
             | 
            
              $ 59.78 | 2.68 % | $ 23.1 B | ||
| 
              
              Organovo Holdings
               ONVO 
              
             | 
            
              $ 2.12 | -2.3 % | $ 19.4 M | ||
| 
              
              Burning Rock Biotech Limited
               BNR 
              
             | 
            
              $ 12.18 | -9.51 % | $ 131 M | ||
| 
              
              Danaher Corporation
               DHR 
              
             | 
            
              $ 214.2 | -0.55 % | $ 157 B | ||
| 
              
              Neogen Corporation
               NEOG 
              
             | 
            
              $ 6.26 | 1.46 % | $ 1.36 B | ||
| 
              
              Biomerica
               BMRA 
              
             | 
            
              $ 2.71 | -0.52 % | $ 6.23 M | ||
| 
              
              Fulgent Genetics
               FLGT 
              
             | 
            
              $ 22.96 | 2.25 % | $ 694 M | ||
| 
              
              Psychemedics Corporation
               PMD 
              
             | 
            
              $ 2.67 | -1.84 % | $ 15.3 M | ||
| 
              
              Genetic Technologies Limited
               GENE 
              
             | 
            
              $ 0.77 | - | $ 7.1 B | ||
| 
              
              Myriad Genetics
               MYGN 
              
             | 
            
              $ 8.03 | -0.19 % | $ 728 M | ||
| 
              
              Renalytix AI plc
               RNLX 
              
             | 
            
              $ 0.21 | 5.66 % | $ 22.7 M | ||
| 
              
              Medpace Holdings
               MEDP 
              
             | 
            
              $ 596.13 | 1.92 % | $ 18.5 B | ||
| 
              
              IQVIA Holdings 
               IQV 
              
             | 
            
              $ 214.25 | -1.05 % | $ 38.8 B | ||
| 
              
              CareDx, Inc
               CDNA 
              
             | 
            
              $ 14.61 | -2.6 % | $ 786 M | ||
| 
              
              Brainsway Ltd.
               BWAY 
              
             | 
            
              $ 17.58 | 4.3 % | $ 99.4 M | ||
| 
              
              Biodesix
               BDSX 
              
             | 
            
              $ 6.33 | -7.3 % | $ 821 M | ||
| 
              
              T2 Biosystems
               TTOO 
              
             | 
            
              $ 0.12 | -39.35 % | $ 313 K | ||
| 
              
              OPKO Health
               OPK 
              
             | 
            
              $ 1.42 | 4.04 % | $ 986 M | ||
| 
              
              Guardant Health
               GH 
              
             | 
            
              $ 98.46 | 5.84 % | $ 12.1 B | ||
| 
              
              Agilent Technologies
               A 
              
             | 
            
              $ 144.14 | -1.5 % | $ 43.8 B | ||
| 
              
              Trinity Biotech plc
               TRIB 
              
             | 
            
              $ 1.0 | - | $ 61.9 M | ||
| 
              
              Co-Diagnostics
               CODX 
              
             | 
            
              $ 0.41 | -10.11 % | $ 12 M |